Milataxel

Drug Profile

Milataxel

Alternative Names: MAC-321; MAC-321 IV; TL 00139; TL-139

Latest Information Update: 10 Feb 2010

Price : $50

At a glance

  • Originator Taxolog
  • Class Antineoplastics; Benzoic acids; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Mesothelioma; Non-small cell lung cancer

Most Recent Events

  • 01 May 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the pharmacokinetics section
  • 13 Oct 2005 Wyeth has reverted the licence for milataxel to Taxolog
  • 02 Sep 2004 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top